Anti PD‐1, anti PD‐L1, and anti CTLA‐4 immunotherapies have shown the most promising outcomes in the treatment of various malignancies including breast cancer, lung cancer, CRC, and melanoma. Here, CTLA4 is linked to breast carcinoma.